Prime Minister Malcolm Turnbull has fulfilled the Coalition’s pledge to spend $54 million subsidising continuous glucose monitoring [CGM] for eligible Australians with Type 1 diabetes. The promise, originally made on 15 May 2016, will be fulfilled from 1 April 2017 for Australians under the age of 21 who meet specific criteria.
This decision reflects years of effort by members of the diabetes community. We congratulate everyone involved.
This is a positive first step in improving diabetes management within our community. However, we realise that it does not provide CGM to everyone and that it should be a continued priority of our community to improve access to all who may benefit. For people who are not eligible, Medtronic will continue to offer CGM subscription packages.
The eligibility criteria for the ‘CGM Initiative’ announced is available from the NDSS and listed below.
|Category (A)||Category (B)|
Children 10 years of age and younger with type 1 diabetes will be eligible for subsidised access to CGM with alarms if they fulfil all of the following criteria:
Those children who turn 11 and have been accessing CGM products through the initiative will continue to have subsidised access. They will not need to be reassessed under Category B.
Children and young people with type 1 diabetes aged from 11 years to less than 21 years will be eligible for subsidised access to CGM with alarms if they fulfil all of the following criteria:
and they fulfil one or more of the following criteria:
For young people in either category, subsidised access to CGM products will cease once they reach 21 years of age.
WHICH MEDTRONIC PRODUCTS ARE COVERED?
Medtronic have four products available through the CGM Initiative; the Enlite™ Sensor, Guardian™ 2 Link, MiniLink transmitter, Guardian Connect™ CGM. CGM technology enables a user to monitor glucose levels 24 hours a day through a sensor.
The varieties of Medtronic CGM in Australia
|Guardian 2 Link CGM||MiniLink CGM||Guardian Connect|
|Pump / Phone Compatibility||MiniMed 640G Pump||Paradigm Veo, Paradigm Real-Time Insulin Pumps||Apple iOS
(iPhone, iPod Touch, iPad)
|Real-time values on receiver||Yes||Yes||Yes|
|Share reports with healthcare professionals||If HCP links CareLink Professional to CareLink Personal, they can access up-to-date reports following patient upload||If HCP links CareLink Professional to CareLink Personal, they can access up-to-date reports following patient upload||If HCP links CareLink Professional to CareLink Personal, they can access up-to-date reports daily|
|Transmitter Memory Storage||10 hours||40 mins||14 days|
|Remote Partner Notification||No||No||Yes, up to 5 registered Care Partners AND optional SMS|
HOW YOU CAN BENEFIT FROM MEDTRONIC CGM
CGM measures and indicates glucose levels continuously [24/7] to assist in monitoring. It can be used by type 1 and type 2 diabetes patients who would like better glucose control to improve the health and quality of their lives – and can help to take the guesswork out of glucose monitoring.
There are two ways you can benefit from Medtronic CGM:
- With an insulin pump. With CGM and the Medtronic Veo or MiniMed 640G Insulin Pump, insulin delivery can be automatically stopped to reduce the occurrence or severity of hypoglycaemia1,2. You’ll have the ability to set alerts to warn about highs or lows, and will see the full picture of glucose levels 24/7 on the device.
- Without an insulin pump. Guardian™ Connect CGM delivers real-time glucose information direct to your iOS device3. You (and any care partners i.e. family members/carers or healthcare professionals) can be alerted if you’re heading towards hypoglycaemia or hyperglycaemia.
This is important because people who are hypo unaware are six times more likely to have severe hypoglycaemia leading to seizures, coma and even death.i Having hypos leads to more hypos and the increased risk of these severe events.
WHAT THIS ANNOUNCEMENT MEANS TO BRENT
Brent Salzmann first championed for the subsidation of CGM as an early-teenager. In 2011 he started a petition requesting government funding for insulin pumps and CGM. He gained support from more than 1,020 community members. Brent shares his thoughts on the decision:
“The government’s decision to fund for continuous glucose monitoring [CGM] on the NDSS for young patients under 21 is a fantastic first step and will help some of the most vulnerable patients have an even greater quality of life.
CGM should be listed on the NDSS because it provides piece of mind not only to yourself but the people surrounding you - It like having another set of eyes that can see very detailed information.
CGM has had a drastic positive impact on my life. I am now pursuing a career that was unimaginable to 16 year old me because I now have information available to me that can't be provided from fingersticks alone.
The next logical step for CGM access on the NDSS would be opening it up to adult patients who have hypo unawareness and eventually to all patients living with Type 1 Diabetes. I can't live without this vital piece of technology and everyone else should have the chance to access it.“
[i] Prevalence of impaired awareness of hypoglycaemia in adults with Type 1 diabetes. Geddes J, Schopman JE, Zammitt NN, Frier BM. Diabet Med. 2008 Apr; 25(4):501-4 (1) Effect of Sensor-Augmented Insulin Pump Therapy and Automated Insulin Suspension vs Standard Insulin Pump Therapy on Hypoglycaemia in Patients With Type 1 Diabetes. A Randomized Clinical Trial. Ly T.T. et al. JAMA 310(12):1240-1247, 2013 (2)Hypoglycemia Prevention and User Acceptance of an Insulin Pump System with Predictive Low Glucose Management. Choudhary et al. DIABETES TECHNOLOGY & THERAPEUTICS Vol 18. No 5, 2016.(3)The Guardian Connect app is compatible with iOS9 and above. The app will be compatible with the following hardware devices: iPhone 4S iPhone 5 iPhone 5C iPhone 5S iPhone 6 iPhone 6 Plus iPhone 6S iPhone 6S Plus iPhone SE iPod Touch (5th generation) iPod Touch (6th generation) iPad 3 iPad 4 iPad Air iPad Air 2 iPad Pro iPad Mini iPad Mini 2 iPad Mini 3 iPad Mini 4. Guardian Connect data cannot be transmitted via a MiniMed Insulin pump.